Related Experiment Videos
Summary
A single 400 mg dose of cefixime effectively treated gonorrhea in male patients. This new oral cephalosporin demonstrated excellent antibacterial activity, curing all evaluable patients without reported side effects.
Area of Science:
- Pharmacology
- Microbiology
- Infectious Diseases
Context:
- Gonorrhea remains a significant public health concern, with increasing resistance to existing treatments.
- Beta-lactamase-positive Neisseria gonorrhoeae strains pose a particular therapeutic challenge.
Purpose:
- To evaluate the efficacy and safety of a single oral dose of cefixime in treating acute gonorrhea.
- To assess the antibacterial activity of cefixime against Neisseria gonorrhoeae, including resistant strains.
Summary:
- A clinical trial involved 14 male patients diagnosed with acute gonorrhea.
- Patients received a single 400 mg oral dose of cefixime.
- All 13 fully evaluable patients achieved clinical and bacteriological cure, with no adverse events reported.
Impact:
- Cefixime presents a promising, effective, and well-tolerated single-dose oral treatment option for gonorrhea.
- This study supports cefixime's utility in combating Neisseria gonorrhoeae infections, including beta-lactamase-producing strains.